Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a fully integrated CNS biopharmaceutical company headquartered in Cambridge, MA, focused on translating insights from genetic epilepsies into therapies for neurological disorders characterized by neuronal excitation-inhibition imbalance. The company operates through two proprietary platforms: Cerebrum, a small molecule platform leveraging computational and experimental tools to develop orally available precision therapies targeting ion channels; and Solidus, an antisense oligonucleotide (ASO) platform using proprietary computational workflows to discover and develop ASOs with optimized drug-like properties. As of the filing date, Praxis employs approximately 168 people and has no manufacturing facilities, relying entirely on third-party CDMOs for clinical and anticipated commercial supply.

Praxis has four clinical-stage product candidates. Ulixacaltamide (PRAX-515) is a highly selective T-type calcium channel inhibitor for essential tremor (ET) — the most common movement disorder affecting roughly 7 million Americans — for which no FDA-approved therapy has offered meaningful efficacy. The FDA granted Breakthrough Therapy...